UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 24, 2021

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

IVERIC bio, Inc.

File No. 1-36080 - CF#36540

IVERIC bio, Inc. (formerly Ophthotech Corporation) submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibit to a Form 10-Q filed on August 1, 2018.

Based on representations by IVERIC bio, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time periods specified:

Exhibit 10.2

through June 6, 2024

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Robert Errett Acting Chief, Disclosure Management Office